Datapoint: J&J Receives Full Approval for Balversa

The FDA on Jan. 19 granted Johnson & Johnson’s Balversa (erdafitinib) full approval for the treatment of locally advanced or metastatic urothelial carcinoma in patients with susceptible FGFR3 genetic alterations who have already received at least one other line of therapy. The FGFR kinase inhibitor was received accelerated approval in 2019 for use in patients with susceptible mutations on the FGFR3 or FGFR2 genes after platinum-based chemotherapy. Notably, patients that have not received a prior PD-1/L1 therapy are ineligible to use Balversa. For the treatment of bladder cancer, the once-daily pill holds covered or betters status for 95% of all insured lives. Just 17% have preferred access, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 1/29/24

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 27

Datapoint: Aetna Sees Strong MA Growth

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 26

Datapoint: Is Medicaid Expansion Coming to Mississippi?

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 22

Datapoint: Baystate to Sell Health Plan to Point32Health

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today